MAXHEALTH - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 2.9

📊 Analysis: Max Healthcare is trading at ₹1,077, below DMA 50 (₹1,123) and DMA 200 (₹1,132), indicating short-term and medium-term weakness. RSI at 34.9 suggests oversold conditions, but MACD negative (-23.3) confirms bearish momentum. Volume (52.5L) is higher than 1-week average (31.9L), showing strong intraday participation. Fundamentals are weak with high P/E (151 vs industry 51.8), PEG ratio (4.79), and declining quarterly PAT (-30.6%). Intraday trades may be possible for speculative rebound near support, but risk remains elevated.

💡 Optimal Buy Price: ₹1,070–₹1,080 (near support zone).

🎯 Profit-Taking Levels: ₹1,095 (first target), ₹1,115 (second target — near DMA 50).

🛡️ Stop-Loss: ₹1,060 (below intraday support).

⏱️ If Already Holding: Exit near ₹1,095–₹1,115 if rebound occurs. Cut position immediately if price falls below ₹1,060 with rising volume, as weakness may extend further.

Positive

• 📈 ROCE 12.5% and ROE 9.45% show moderate efficiency
• 💹 DII holding increased (+2.62%), showing strong domestic support
• 📊 Volume higher than average, indicating active intraday participation
• 📉 Debt-to-equity 0.08 ensures financial stability

Limitation

• 📉 P/E 151 much higher than industry average (51.8)
• 📊 PEG ratio 4.79 indicates overvaluation relative to growth
• 📉 Price below DMA 50 & DMA 200, confirming bearish trend
• 📊 Quarterly PAT dropped from ₹166 Cr. to ₹160 Cr.

Company Negative News

• ⚠️ Quarterly profit decline (-30.6%) impacting sentiment
• ⚠️ FII holding decreased (-2.96%), showing reduced foreign confidence

Company Positive News

• ✅ DII holding increased (+2.62%), showing strong domestic institutional support
• ✅ EPS ₹6.60 reflects earnings despite valuation concerns

Industry

• 🏥 Industry PE at 51.8, Max Healthcare at 151 — highly overvalued
• 📊 Healthcare sector remains defensive but valuations are stretched

Conclusion

🔎 Max Healthcare is a weak intraday candidate with bearish technicals and stretched valuations, though oversold RSI and high volume may trigger short-term rebound. Buy zone is ₹1,070–₹1,080 with targets at ₹1,095 and ₹1,115. Maintain strict stop-loss at ₹1,060. If already holding, exit near targets or cut losses below support with volume confirmation.

Would you like me to extend this into a peer benchmarking overlay with other hospital chains like Apollo Hospitals and Fortis or a sector rotation basket scan to validate intraday opportunities?